T. Rowe Price Associates’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $406K | Buy |
|
|||||
|
2025
Q2 | $386K | Buy |
|
|||||
|
2025
Q1 | $284K | Buy |
|
|||||
|
2024
Q4 | $314K | Sell |
|
|||||
|
2024
Q3 | $359K | Buy |
|
|||||
|
2024
Q2 | $228K | Buy |
|
|||||
|
2024
Q1 | $264K | Buy |
|
|||||
|
2023
Q4 | $474K | Buy |
|
|||||
|
2023
Q3 | $325K | Buy |
|
|||||
|
2023
Q2 | $353K | Buy |
|
|||||
|
2023
Q1 | $365K | Buy |
|
|||||
|
2022
Q4 | $390K | Buy |
|
|||||
|
2022
Q3 | $428K | Buy |
|
|||||
|
2022
Q2 | $370K | Buy |
|
|||||
|
2022
Q1 | $449K | Buy |
|
|||||
|
2021
Q4 | $550K | Buy |
|
|||||
|
2021
Q3 | $557K | Buy |
|
|||||
|
2021
Q2 | $483K | Sell |
|
|||||
|
2021
Q1 | $324K | Sell |
|
|||||
|
2020
Q4 | $356K | Sell |
|
|||||
|
2020
Q3 | $410K | Sell |
|
|||||
|
2020
Q2 | $444K | Sell |
|
|||||
|
2020
Q1 | $362K | Buy |
|
|||||
|
2019
Q4 | $78K | Buy |
|
|||||
|
2019
Q3 | $90K | Buy |
|
|||||
|
2019
Q2 | $95K | Buy |
|
|||||
|
2019
Q1 | $84K | Buy |
|
|||||
|
2018
Q4 | $42K | Sell |
|
|||||
|
2018
Q3 | $153K | Buy |
|
|||||
|
2018
Q2 | $146K | Buy |
|
|||||
|
2018
Q1 | $153K | Buy |
|
|||||
|
2017
Q4 | $178K | Buy |
|
|||||
|
2017
Q3 | $224K | Buy |
|
|||||
|
2017
Q2 | $285K | Buy |
|
|||||
|
2017
Q1 | $306K | Buy |
|
|||||
|
2016
Q4 | $118K | Hold |
|
|||||
|
2016
Q3 | $108K | Buy |
|